This afternoon we watched United Therapeutics drop -12.0% to a price of $314.62 per share. The Large-Cap Pharmaceutical company is now trading -22.15% below its average target price of $404.16. Analysts have set target prices ranging from $302.0 to $600.0 per share for United Therapeutics, and have given the stock an average rating of buy.
United Therapeutics has an average level of shares sold short, at 5.9% of its total share float. The stock's short ratio (also called days to cover) is 6.81. The company's insiders own 1.98% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 101.2% of United Therapeutics's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in United Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | Blackrock Inc. | 12% | 5,358,332 | $1,685,838,387 |
| 2024-12-31 | Vanguard Group Inc | 10% | 4,441,823 | $1,397,486,330 |
| 2024-12-31 | Avoro Capital Advisors LLC | 6% | 2,760,300 | $868,445,572 |
| 2024-12-31 | Wellington Management Group, LLP | 6% | 2,463,891 | $775,189,374 |
| 2024-12-31 | State Street Corporation | 5% | 2,199,994 | $692,162,101 |
| 2024-12-31 | Renaissance Technologies, LLC | 5% | 2,089,392 | $657,364,500 |
| 2024-12-31 | FMR, LLC | 3% | 1,471,405 | $462,933,433 |
| 2024-12-31 | Geode Capital Management, LLC | 3% | 1,138,292 | $358,129,423 |
| 2024-12-31 | AQR Capital Management, LLC | 2% | 975,444 | $306,894,186 |
| 2024-12-31 | LSV Asset Management | 2% | 908,724 | $285,902,740 |
